Analysis of contact tracing data showed contribution of asymptomatic and non-severe infections to the maintenance of SARS-CoV-2 transmission in Senegal.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 06 2023
05 06 2023
Historique:
received:
18
01
2023
accepted:
21
05
2023
medline:
7
6
2023
pubmed:
6
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
During the COVID-19 pandemic in Senegal, contact tracing was done to identify transmission clusters, their analysis allowed to understand their dynamics and evolution. In this study, we used information from the surveillance data and phone interviews to construct, represent and analyze COVID-19 transmission clusters from March 2, 2020, to May 31, 2021. In total, 114,040 samples were tested and 2153 transmission clusters identified. A maximum of 7 generations of secondary infections were noted. Clusters had an average of 29.58 members and 7.63 infected among them; their average duration was 27.95 days. Most of the clusters (77.3%) are concentrated in Dakar, capital city of Senegal. The 29 cases identified as super-spreaders, i.e., the indexes that had the most positive contacts, showed few symptoms or were asymptomatic. Deepest transmission clusters are those with the highest percentage of asymptomatic members. The correlation between proportion of asymptomatic and degree of transmission clusters showed that asymptomatic strongly contributed to the continuity of transmission within clusters. During this pandemic, all the efforts towards epidemiological investigations, active case-contact detection, allowed to identify in a short delay growing clusters and help response teams to mitigate the spread of the disease.
Identifiants
pubmed: 37277417
doi: 10.1038/s41598-023-35622-6
pii: 10.1038/s41598-023-35622-6
pmc: PMC10240476
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9121Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Sci Rep. 2021 Apr 21;11(1):8605
pubmed: 33883590
Emerg Infect Dis. 2020 Nov;26(11):2772-2774
pubmed: 33054907
F1000Res. 2018 May 10;7:566
pubmed: 31240097
Breathe (Sheff). 2018 Jun;14(2):131-140
pubmed: 29875832
Int J Infect Dis. 2020 Aug;97:21-22
pubmed: 32497799
BMC Infect Dis. 2021 May 19;21(1):453
pubmed: 34011266
Int J Infect Dis. 2011 Aug;15(8):e510-3
pubmed: 21737332
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nat Med. 2020 Sep;26(9):1398-1404
pubmed: 32647358
Sci Rep. 2019 Feb 20;9(1):2348
pubmed: 30787335
Genes Dis. 2020 Dec;7(4):558-566
pubmed: 32837986
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971